1 – 10 of 21
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma : Real-world evidence from Sweden
(
- Contribution to journal › Article
- 2022
-
Mark
Regional differences in treatment and outcome for myeloma patients in Sweden : A population based Swedish myeloma register study
(
- Contribution to journal › Article
-
Mark
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma : A randomised phase 2 trial by the Nordic Myeloma Study Group
(
- Contribution to journal › Article
- 2021
-
Mark
Burden of Treatment-Induced Peripheral Neuropathy in Patients with Multiple Myeloma in Sweden
(
- Contribution to journal › Article
- 2020
-
Mark
Outcome and characteristics of non-measurable myeloma : A cohort study with population-based data from the Swedish Myeloma Registry
(
- Contribution to journal › Article
- 2019
-
Mark
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
(
- Contribution to journal › Article
- 2018
-
Mark
Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry
(
- Contribution to journal › Article
-
Mark
The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression
(
- Contribution to journal › Article
-
Mark
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma
(
- Contribution to journal › Article
- 2017
-
Mark
Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register
(
- Contribution to journal › Article